

|  |   |     |
|--|---|-----|
| Informazione<br>Regolamentata n.<br>0696-36-2015 | Data/Ora Ricezione<br>24 Marzo 2015<br>01:44:55 | MTA |
|--|---|-----|

Societa' : CTI BIOPHARMA

Identificativo : 55054

Informazione  
Regolamentata

Nome utilizzatore : CELLN01 - Villa

Tipologia : AVVI 08

Data/Ora Ricezione : 24 Marzo 2015 01:44:55

Data/Ora Inizio : 24 Marzo 2015 01:59:55

Diffusione presunta

Oggetto : CTI BioPharma Corp.: CTI BioPharma Files  
Amended and Restated Articles of  
Incorporation

*Testo del comunicato*

Vedi allegato.



## **CTI BioPharma Files Amended and Restated Articles of Incorporation**

SEATTLE, MARCH 23, 2015 – CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that it has filed with the Secretary of State of the State of Washington an amended and restated articles of incorporation. CTI BioPharma has filed a Current Report on Form 8-K, including a copy of the amended and restated articles of incorporation, with the U.S. Securities and Exchange Commission. Copies of such amended and restated articles of incorporation and Current Report on Form 8-K is on file and available for review on CTI BioPharma’s website at [www.ctibiopharma.com](http://www.ctibiopharma.com), on the Securities and Exchange Commission’s website at [www.sec.gov](http://www.sec.gov), and on the authorized storage system “NIS Storage” website [www.emarketstorage.com](http://www.emarketstorage.com).

### **About CTI BioPharma**

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit [www.ctibiopharma.com](http://www.ctibiopharma.com).

Source: CTI BioPharma Corp.

###

#### **Contacts:**

Monique Greer  
+1 206-272-4343  
[mgreer@ctibiopharma.com](mailto:mgreer@ctibiopharma.com)

Ed Bell  
+1 206-282-7100  
[ebell@ctibiopharma.com](mailto:ebell@ctibiopharma.com)

In Europe: CTI Life Sciences Limited, Milan  
Branch  
Laura Villa  
+39 02 94751572  
[lvilla@cti-lifesciences.com](mailto:lvilla@cti-lifesciences.com)

Fine Comunicato n.0696-36

Numero di Pagine: 3